Galmed Pharmaceuticals LTD. (GLMD) SEC Filings — 2025
24 SEC filings for Galmed Pharmaceuticals LTD. (GLMD) in 2025.
Filings
- Galmed Pharma's Aramchol Abstract Accepted for HEP-DART 2025 — 6-K · Dec 8, 2025
- Galmed Pharma Secures New Patents for Aramchol Combination Therapy — 6-K · Dec 4, 2025
- Galmed Pharmaceuticals LTD. 6-K Filing — 6-K · Dec 1, 2025
- Galmed Pharma Files 6-K with Q3 2025 Financials — 6-K · Nov 26, 2025
- Galmed Pharma Reports Aramchol Study Results — 6-K · Nov 18, 2025
- Galmed Pharma: Aramchol Combo Shows Promise in GI Cancer Studies — 6-K · Nov 17, 2025
- Galmed Pharmaceuticals Holds Annual Shareholder Meeting — 6-K · Oct 29, 2025
- Galmed Pharma AGM Adjourned Due to Lack of Quorum — 6-K · Oct 28, 2025
- Galmed Pharmaceuticals Sets Annual Shareholder Meeting Date — 6-K · Sep 19, 2025
- Galmed Pharma Files 6-K with Q2 2025 Financials — 6-K · Aug 28, 2025
- Galmed Pharma Unveils Digital Asset Strategy, Terminates Deal — 6-K · Aug 25, 2025
- Galmed Pharmaceuticals Holds Shareholder Meeting — 6-K · Aug 15, 2025
- Galmed Pharma Shareholder Meeting Adjourned Due to Lack of Quorum — 6-K · Aug 14, 2025
- Galmed Pharmaceuticals Sets Shareholder Meeting for August 14 — 6-K · Jul 24, 2025
- Galmed Pharma Identifies Biomarker for Aramchol Expansion — 6-K · May 27, 2025
- Galmed Pharma Files 6-K with Q1 2025 Financials — 6-K · May 22, 2025
- Galmed Pharma Reports Aramchol's Anti-Fibrotic Effects in PSC Models — 6-K · May 13, 2025
- Galmed's Aramchol Boosts Bayer's Regorafenib in Cancer Studies — 6-K · May 6, 2025
- Galmed Pharma Signs Term Sheet for Novel Semaglutide Formulation — 6-K · Apr 28, 2025
- Galmed Pharma partners with VCU on GI cancer drug resistance — 6-K · Apr 17, 2025
- Galmed Pharma unveils Aramchol blood markers — 6-K · Apr 15, 2025
- Galmed Pharma Reports Positive Aramchol Meglumine Study Results — 6-K · Apr 10, 2025
- Galmed Pharmaceuticals Files 2024 Annual Report — 20-F · Apr 2, 2025
- Galmed Pharma Secures Patent Extension for Aramchol to 2039 — 6-K · Mar 20, 2025